These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 26516157)

  • 1. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
    Milutinovic S; Kashyap AK; Yanagi T; Wimer C; Zhou S; O'Neil R; Kurtzman AL; Faynboym A; Xu L; Hannum CH; Diaz PW; Matsuzawa S; Horowitz M; Horowitz L; Bhatt RR; Reed JC
    Mol Cancer Ther; 2016 Jan; 15(1):114-24. PubMed ID: 26516157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
    Yang J; Li G; Zhang K
    Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
    Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
    Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.
    Abdulghani J; Allen JE; Dicker DT; Liu YY; Goldenberg D; Smith CD; Humphreys R; El-Deiry WS
    PLoS One; 2013; 8(9):e75414. PubMed ID: 24086526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes.
    Allen JE; Ferrini R; Dicker DT; Batzer G; Chen E; Oltean DI; Lin B; Renshaw MW; Kretz-Rommel A; El-Deiry WS
    Mol Cancer Ther; 2012 Oct; 11(10):2087-95. PubMed ID: 22802267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
    Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
    van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
    BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
    Liu Y; Hawkins OE; Vilgelm AE; Pawlikowski JS; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
    Clin Cancer Res; 2015 Dec; 21(23):5338-48. PubMed ID: 26152738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
    Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
    J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Death receptor 5 is activated by fucosylation in colon cancer cells.
    Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
    FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.
    Bychkov ML; Gasparian ME; Dolgikh DA; Kirpichnikov MP
    PLoS One; 2014; 9(10):e109756. PubMed ID: 25310712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lupulone, a hop bitter acid, activates different death pathways involving apoptotic TRAIL-receptors, in human colon tumor cells and in their derived metastatic cells.
    Lamy V; Roussi S; Chaabi M; Gossé F; Lobstein A; Raul F
    Apoptosis; 2008 Oct; 13(10):1232-42. PubMed ID: 18726190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5.
    Chen JJ; Mikelis CM; Zhang Y; Gutkind JS; Zhang B
    Oncotarget; 2013 Feb; 4(2):206-17. PubMed ID: 23470485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.
    Di X; Zhang G; Zhang Y; Takeda K; Rivera Rosado LA; Zhang B
    Oncotarget; 2013 Sep; 4(9):1349-64. PubMed ID: 23988408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
    Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
    Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization.
    Dubuisson A; Favreau C; Fourmaux E; Lareure S; Rodrigues-Saraiva R; Pellat-Deceunynck C; El Alaoui S; Micheau O
    Cell Death Dis; 2019 Feb; 10(2):101. PubMed ID: 30718507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
    Jang JY; Jeon YK; Choi Y; Kim CW
    Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.